2024
Tuberculosis Preventive Treatment for Pregnant People With Human Immunodeficiency Virus in South Africa: A Modeling Analysis of Clinical Benefits and Risks
Rosen L, Thielking A, Dugdale C, Montepiedra G, Kalk E, Kim S, LaCourse S, Mathad J, Freedberg K, Horsburgh C, Paltiel A, Wood R, Ciaranello A, Reddy K. Tuberculosis Preventive Treatment for Pregnant People With Human Immunodeficiency Virus in South Africa: A Modeling Analysis of Clinical Benefits and Risks. Clinical Infectious Diseases 2024, ciae508. PMID: 39544107, DOI: 10.1093/cid/ciae508.Peer-Reviewed Original ResearchAdverse pregnancy outcomesHuman immunodeficiency virusRisk of stillbirthFetal/infant deathImmunodeficiency virusHigher risk of LBWMaternal CD4 cell countCD4 cell countMonths of isoniazidRisk of LBWPregnant peopleHigher-risk scenarioTuberculosis preventive treatmentIsoniazid-rifapentineAntiretroviral therapyPregnancy outcomesClinical benefitPrimary outcomeCombined deathPreventive treatmentCell countHigh riskStillbirthPregnancyInternational guidelinesTobacco smoking, smoking cessation and life expectancy among people with HIV on antiretroviral therapy in South Africa: a simulation modelling study
Thielking A, Fitzmaurice K, Sewpaul R, Chrysanthopoulou S, Dike L, Levy D, Rigotti N, Siedner M, Wood R, Paltiel A, Freedberg K, Hyle E, Reddy K. Tobacco smoking, smoking cessation and life expectancy among people with HIV on antiretroviral therapy in South Africa: a simulation modelling study. Journal Of The International AIDS Society 2024, 27: e26315. PMID: 38924347, PMCID: PMC11197963, DOI: 10.1002/jia2.26315.Peer-Reviewed Original ResearchConceptsMortality hazard ratioSmoking cessationLife yearsNever smoking statusLife expectancyVirologically suppressed PWHSmoking statusTobacco smokeIntegrate tobacco cessation interventionsMortality riskHazard ratioTobacco cessation interventionsSmoking cessation increasesTobacco-related illnessesImpact of tobacco smokingAntiretroviral therapyMortality risk increaseProportion of deathsChronic respiratory conditionsImpact of smokingCohort of PWHVirological non-suppressionCessation interventionsVirologic suppressionHIV care
2023
Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price
Amick A, Eskibozkurt G, Hosek S, Flanagan C, Landovitz R, Jin E, Wilson C, Freedberg K, Weinstein M, Kazemian P, Paltiel A, Ciaranello A, Neilan A. Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price. Clinical Infectious Diseases 2023, 78: 402-410. PMID: 37823865, PMCID: PMC10874274, DOI: 10.1093/cid/ciad566.Peer-Reviewed Original ResearchPre-exposure prophylaxisHIV incidenceRisk of HIVOral PrEPAnnual screeningHuman immunodeficiency virus (HIV) pre-exposure prophylaxisOral HIV pre-exposure prophylaxisHIV pre-exposure prophylaxisIncremental cost-effectiveness ratioHIV RNA levelsYoung menCost-effectiveness ratioAnnual HIVHigher discontinuationPrEP retentionAntiretroviral therapyDrug pricesHIV careLow adherenceLifetime horizonNew infectionsHIVIncidencePrEPRNA levels
2018
The cost‐effectiveness and budgetary impact of a dolutegravir‐based regimen as first‐line treatment of HIV infection in India
Zheng A, Kumarasamy N, Huang M, Paltiel AD, Mayer KH, Rewari BB, Walensky RP, Freedberg KA. The cost‐effectiveness and budgetary impact of a dolutegravir‐based regimen as first‐line treatment of HIV infection in India. Journal Of The International AIDS Society 2018, 21: e25085. PMID: 29603882, PMCID: PMC5878415, DOI: 10.1002/jia2.25085.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioStandard of careAntiretroviral therapyTenofovir disoproxil fumarateHIV infectionRecent guidelinesFirst-line antiretroviral therapyFirst-line HIV treatmentLifetime incremental cost-effectiveness ratioART-naive patientsDolutegravir-based regimenDTG-based regimenFirst-line treatmentClinical trial dataCost-effectiveness ratioLifetime care costsInitial therapyVirologic suppressionCD4 countHIV diseaseRegimen costsDisoproxil fumarateHIV treatmentAIDS complicationsCare costs
2017
Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States
Reddy KP, Kong CY, Hyle EP, Baggett TP, Huang M, Parker RA, Paltiel AD, Losina E, Weinstein MC, Freedberg KA, Walensky RP. Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States. JAMA Internal Medicine 2017, 177: 1613-1621. PMID: 28975270, PMCID: PMC5675744, DOI: 10.1001/jamainternmed.2017.4349.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusLung cancer mortalityAge 40 yearsAntiretroviral therapyLung cancerCancer mortalityLower lung cancer mortalityIncomplete ART adherenceLung cancer deathsAge 80 yearsRisk of deathMortality risk ratioHigher overall mortalityStandard demographic dataGreater AIDSLight smokersSmoking exposureCurrent smokersFormer smokersART adherenceModerate smokersOverall mortalitySmoking habitsSmoking statusImmunodeficiency virusA Flow-Based Model of the HIV Care Continuum in the United States
Gonsalves GS, Paltiel AD, Cleary PD, Gill MJ, Kitahata MM, Rebeiro PF, Silverberg MJ, Horberg M, Abraham AG, Althoff KN, Moore R, Bosch RJ, Tang T, Hall HI, Kaplan EH. A Flow-Based Model of the HIV Care Continuum in the United States. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2017, 75: 548-553. PMID: 28471841, PMCID: PMC5533168, DOI: 10.1097/qai.0000000000001429.Peer-Reviewed Original ResearchConceptsViral suppressionAntiretroviral therapyHIV careNorth American AIDS Cohort CollaborationProportion of HIVHIV care continuumCohort CollaborationHIV diagnosisAntiretroviral treatmentVirological dataCare continuumFlow of patientsDisease controlPatientsCareAverage timeHIVTherapyLaboratory resultsMonthsSuppressionYearsDiagnosisIndividualsPreventionSetting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa
Paltiel AD, Zheng A, Weinstein MC, Gaynes MR, Wood R, Freedberg KA, Sax PE, Walensky RP. Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa. Open Forum Infectious Diseases 2017, 4: ofx081. PMID: 28680903, PMCID: PMC5490502, DOI: 10.1093/ofid/ofx081.Peer-Reviewed Original ResearchHIV cure strategiesCure strategiesHuman immunodeficiency virus (HIV) eradicationLifetime antiretroviral therapySustained viral eradicationElimination of HIVStandard of careLifetime costsAntiretroviral therapyViral eradicationHIV cureFatal toxicitySingle interventionVirus eradicationLife expectancyCureLower lifetime costsSingle caseSurvival
2016
Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study
Reddy KP, Parker RA, Losina E, Baggett TP, Paltiel AD, Rigotti NA, Weinstein MC, Freedberg KA, Walensky RP. Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study. The Journal Of Infectious Diseases 2016, 214: 1672-1681. PMID: 27815384, PMCID: PMC5144729, DOI: 10.1093/infdis/jiw430.Peer-Reviewed Original ResearchConceptsSmoking statusSmoking cessationUS smokersLife expectancyT-cell countsHIV treatment programsAge 40 yearsYears of lifeSex-specific dataAntiretroviral therapyInitial CD4Current smokersFormer smokersHIV diseaseHIV infectionCigarette smokingMortality riskSmokersHIVSmoke cigarettesYounger ageTreatment programCessation ageSmokingCessationLaboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies
Ouattara EN, Robine M, Eholié SP, MacLean RL, Moh R, Losina E, Gabillard D, Paltiel AD, Danel C, Walensky RP, Anglaret X, Freedberg KA. Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies. Clinical Infectious Diseases 2016, 62: 1454-1462. PMID: 26936666, PMCID: PMC4872286, DOI: 10.1093/cid/ciw117.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioAntiretroviral therapyHuman immunodeficiency virusImmunologic failureLaboratory monitoringAIDS Complications-International modelFirst-line antiretroviral therapyBudget impactSecond-line antiretroviral therapyMean CD4 countStandard of careCost-effectiveness ratioLaboratory test costsCD4 monitoringART initiationCD4 countHIV infectionVL monitoringClinical outcomesImmunodeficiency virusCôte d'IvoireMean timeLife expectancyTherapyVL strategiesSurvival benefits of antiretroviral therapy in Brazil: a model‐based analysis
Luz PM, Girouard MP, Grinsztejn B, Freedberg KA, Veloso VG, Losina E, Struchiner CJ, MacLean RL, Parker RA, Paltiel AD, Walensky RP. Survival benefits of antiretroviral therapy in Brazil: a model‐based analysis. Journal Of The International AIDS Society 2016, 19: 20623. PMID: 27029828, PMCID: PMC4814587, DOI: 10.7448/ias.19.1.20623.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyHIV-positive patientsSurvival benefitART initiationEligible HIV-positive patientsProvision of ARTDramatic survival benefitsSubsequent ART regimensMean CD4 countLife expectancyNumber of patientsProjected life expectancyART regimensCD4 countHigher CD4HIV diseaseRegimen efficacyLife expectancy increasesEra 1PatientsTherapyNational programExpectancyCD4Regimens
2015
The Epi-TAF for Tenofovir Disoproxil Fumarate?
Walensky RP, Horn TH, Paltiel AD. The Epi-TAF for Tenofovir Disoproxil Fumarate? Clinical Infectious Diseases 2015, 62: 915-918. PMID: 26658300, DOI: 10.1093/cid/civ1000.Peer-Reviewed Original ResearchConceptsTenofovir disoproxil fumarateAverage wholesale priceDisoproxil fumarateBone mineral density lossHIV treatment regimenTenofovir/lamivudineImproved toxicity profileHuman immunodeficiency virusMineral density lossAntiretroviral therapyRenal injuryTenofovir alafenamideTreatment regimenImmunodeficiency virusEqual efficacyToxicity profileCost-effectiveness methodsDensity lossUS residentsAlafenamideRegimenLamivudineTherapyInjuryFumarateThe Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States
Girouard MP, Sax PE, Parker RA, Taiwo B, Freedberg KA, Gulick RM, Weinstein MC, Paltiel AD, Walensky RP. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States. Clinical Infectious Diseases 2015, 62: 784-791. PMID: 26658053, PMCID: PMC4772845, DOI: 10.1093/cid/civ981.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioStandard of careVirologic suppressionART costsBudget impactHuman immunodeficiency virus (HIV) treatmentART-naive patientsDTG/ABC/3TCVirologic suppression ratesSubsequent virologic failureCost-effectiveness ratioPerson/yearInitial regimenAntiretroviral therapyInduction regimenNaive patientsVirologic failureAntiretroviral agentsDual therapyHIV infectionTwo-drugDolutegravirVirus treatmentRegimenSurvival ratePrioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US
Pei PP, Weinstein MC, Li XC, Hughes MD, Paltiel AD, Hou T, Parker RA, Gaynes MR, Sax PE, Freedberg KA, Schackman BR, Walensky RP. Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US. HIV Research & Clinical Practice 2015, 16: 207-218. PMID: 26651525, PMCID: PMC4718767, DOI: 10.1080/15284336.2015.1123942.Peer-Reviewed Original ResearchConceptsGeneric antiretroviral therapyAntiretroviral therapyProbabilistic sensitivity analysesTreatment changesFirst-line ART regimensMore treatment changesComparative effectiveness trialTwo-arm trialImproved health outcomesTwo-pillART regimensHIV careART failureEffectiveness trialTrial completionRNA suppressionHealth outcomesFuture patientsPatientsCost-effective strategyTrialsRegimenRegimensHIVTherapyThe Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy
Ross EL, Weinstein MC, Schackman BR, Sax PE, Paltiel AD, Walensky RP, Freedberg KA, Losina E. The Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy. Clinical Infectious Diseases 2015, 60: 1102-1110. PMID: 25583979, PMCID: PMC4366583, DOI: 10.1093/cid/ciu1159.Peer-Reviewed Original ResearchConceptsDaily ART adherenceAnnual drug costsART adherenceLA-ARTAntiretroviral therapyDrug costsART-naive patientsDaily oral ARTHIV RNA suppressionSecond-line therapyFirst-line therapyFirst-line regimensHuman immunodeficiency virusDaily ARTOverall life expectancyHIV patientsAdherent patientsAvailable regimensART failureImmunodeficiency virusClinical rolePatientsRNA suppressionTherapyAnnual cost
2014
Clinical Impact and Cost-Effectiveness of Making Third-Line Antiretroviral Therapy Available in Sub-Saharan Africa
Ouattara EN, Ross EL, Yazdanpanah Y, Wong AY, Robine M, Losina E, Moh R, Walensky RP, Danel C, Paltiel AD, Eholié SP, Freedberg KA, Anglaret X. Clinical Impact and Cost-Effectiveness of Making Third-Line Antiretroviral Therapy Available in Sub-Saharan Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2014, 66: 294-302. PMID: 24732870, PMCID: PMC4146647, DOI: 10.1097/qai.0000000000000166.Peer-Reviewed Original ResearchConceptsThird-line antiretroviral therapySecond-line antiretroviral therapyIncremental cost-effectiveness ratioAntiretroviral therapyAdherence reinforcementClinical impactSecond-line ART failureLifetime incremental cost-effectiveness ratioRaltegravir-based regimenSecond-line regimenTen-year survivalSubstantial survival benefitCost-effectiveness ratioPrimary outcomeSurvival benefitART failureDrug costsImmediate switchRegimenPatientsTherapyReinforcement interventionSaharan AfricaSurvivalSub-Saharan Africa
2013
The Survival Benefits of Antiretroviral Therapy in South Africa
April MD, Wood R, Berkowitz BK, Paltiel AD, Anglaret X, Losina E, Freedberg KA, Walensky RP. The Survival Benefits of Antiretroviral Therapy in South Africa. The Journal Of Infectious Diseases 2013, 209: 491-499. PMID: 24307741, PMCID: PMC3903379, DOI: 10.1093/infdis/jit584.Peer-Reviewed Original ResearchConceptsSecond-line antiretroviral therapyAntiretroviral therapySurvival benefitAIDS Complications-International modelTotal survival benefitT-cell countsHuman immunodeficiency virusART initiationART rolloutUntreated patientsImmunodeficiency virusART availabilitySurvival differencesSuppressive efficacyCohortPatientsTherapyTotal numberRetention ratePersonsBenefitsCost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples
Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, Nakamura YM, Godbole SV, Panchia R, Sanne I, Weinstein MC, Losina E, Mayer KH, Chen YQ, Wang L, McCauley M, Gamble T, Seage GR, Cohen MS, Freedberg KA. Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples. New England Journal Of Medicine 2013, 369: 1715-1725. PMID: 24171517, PMCID: PMC3913536, DOI: 10.1056/nejmsa1214720.Peer-Reviewed Original ResearchConceptsEarly antiretroviral therapyHuman immunodeficiency virusAntiretroviral therapySerodiscordant couplesHIV transmissionHIV Prevention Trials Network 052 studyIncremental cost-effectiveness ratioCost-effectiveness ratioResource-limited settingsHIV infectionClinical benefitImmunodeficiency virusHIV treatmentLonger survivalOpportunistic diseasesEarly initiationFive yearsLifetime outcomesPublic healthSuch personsPatientsPeriodTherapyInfectionDisease
2012
Newer drugs and earlier treatment
Sloan CE, Champenois K, Choisy P, Losina E, Walensky RP, Schackman BR, Ajana F, Melliez H, Paltiel AD, Freedberg KA, Yazdanpanah Y. Newer drugs and earlier treatment. AIDS 2012, 26: 45-56. PMID: 22008655, PMCID: PMC3237010, DOI: 10.1097/qad.0b013e32834dce6e.Peer-Reviewed Original ResearchConceptsCD4 cell countAntiretroviral therapyHIV RNACD4 cellsHIV diseaseCells/Life expectancyCell countMean CD4 cell countMean age 38 yearsAge 38 yearsMedical resource utilizationLifetime costsUndiscounted life expectancyCost of careAIDS Complications (CEPAC) modelART initiationHIV CostRegimen costsAntiretroviral drugsART costsEarly treatmentCopies/High-income countriesEfficacious drugs
2011
The Clinical Impact and Cost-Effectiveness of Routine, Voluntary HIV Screening in South Africa
Walensky RP, Wood R, Fofana MO, Martinson NA, Losina E, April MD, Bassett IV, Morris BL, Freedberg KA, Paltiel AD. The Clinical Impact and Cost-Effectiveness of Routine, Voluntary HIV Screening in South Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: 26-35. PMID: 21068674, PMCID: PMC3005842, DOI: 10.1097/qai.0b013e3181fb8f24.Peer-Reviewed Original ResearchConceptsVoluntary HIV screeningQuality-adjusted life yearsHIV screeningLife yearsHIV case detectionHIV testing costsTest acceptance rateIncremental cost-effectiveness ratioSubstantial clinical benefitIncidence/prevalenceOne-time screeningDirect medical costsLife expectancyQuality-adjusted life expectancyCost-effectiveness ratioAntiretroviral therapyAnnual incidenceClinical benefitHIV prevalenceClinical impactCase detectionMedical costsCare ratesHIVTest acceptance
2010
Test and Treat DC: Forecasting the Impact of a Comprehensive HIV Strategy in Washington DC
Walensky RP, Paltiel AD, Losina E, Morris BL, Scott CA, Rhode ER, Seage GR, Freedberg KA, Investigators F. Test and Treat DC: Forecasting the Impact of a Comprehensive HIV Strategy in Washington DC. Clinical Infectious Diseases 2010, 51: 392-400. PMID: 20617921, PMCID: PMC2906630, DOI: 10.1086/655130.Peer-Reviewed Original ResearchConceptsHIV RNA levelsAntiretroviral therapyLife expectancyAdministration of ARTHuman immunodeficiency virus (HIV) epidemicART initiation strategiesHIV case detectionRNA levelsUndiagnosed HIV prevalenceCells/microLEarly case identificationInitial mean ageRegular screening programsHIV screeningHIV testAnnual incidenceAnnual screeningHIV prevalenceHIV transmissionHIV strategiesMean ageHIV epidemicCase detectionScreening programART efficacy